false
OasisLMS
Login
Catalog
Kidney Week 2026 Early Program On-Demand - Onconep ...
Kidney Transplant Onconephrology: Immunotherapies, ...
Kidney Transplant Onconephrology: Immunotherapies, Engineered Cellular Therapies, and Management of Post-Transplant Lymphoproliferative Disorder
Back to course
[Please upgrade your browser to play this video content]
Video Transcription
Video Summary
Dr. Naoka Murakami discussed cancer treatment in kidney transplant recipients, focusing on immune checkpoint inhibitors and cellular therapies. Cancer is a growing cause of death after transplantation, but checkpoint inhibitors can trigger rapid, severe rejection: one multicenter study found rejection in 42% of recipients, often within weeks. Evidence suggests switching calcineurin inhibitors to an mTOR inhibitor and using a tailored steroid regimen may reduce rejection while preserving tumor response. Treatment requires close multidisciplinary planning and monitoring.<br /><br />She also reviewed post-transplant lymphoproliferative disorder (PTLD), often associated with Epstein–Barr virus. Initial treatment commonly involves reducing immunosuppression, with rituximab-based therapy and, when needed, CAR-T or other cellular therapies. CAR-T treatment requires minimizing immunosuppression to support T-cell activity, while carefully managing rejection and kidney injury risks. Overall, emerging cancer therapies may benefit transplant recipients, but immunosuppression must be individualized and graft function closely monitored.
Asset Caption
Naoka Murakami, MD, PhD, FASN
Meta Tag
Speaker
Naoka Murakami
Keywords
kidney transplant recipients
immune checkpoint inhibitors
organ rejection
post-transplant lymphoproliferative disorder
rituximab therapy
CAR-T cell therapy
×
Please select your language
1
English